الفهرس 
A Clinicopathologic study of patients with neuroendocrine tumors who presented to the National Cancer Institute in the period from 2010 to 2014
contentsOnly 14 pages are availabe for public view
 |  | from | 98 |  |  |
| | | from | 98 | | |
Abstract
Introduction and aim of the work: Neuroendocrine tumors are a rare type of neoplasms that show a rising incidence over the past few decades. In this study we compare the clinicopathological features of the different neuroendocrine tumors. Patients and methods: This is a retrospective study that included all pathologically proven neuroendocrine tumors who presented to National Cancer Institute in Egypt (NCI-E) in the period from January 2010 to December 2014. Data of patients were collected from the medical records at the cancer epidemiology and biostatistics department, NCI. Results: During this period 115 patients were assessed, they were divided into 4 major groups according the site of primary (GEP, Lung, breast, PCC/PGL), the mean age was 51.7±12.8 (median 54, range 18-81), with an F:M ratio of 1.2:1. The lung cases had a higher male predominance and most of them presented at stage IV while the rest of the cases presented at earlier stages.Most of the breast cases were obese and they had higher rates of co-morbidities. Calculation of survival showed the OSat 5 years of breast, lung, PCC/PGL and GEP NETs cases were 69%, 20%, 77% and 52% respectively, non of the groups reached a median survival except the lung cases (13.7 months). Univariate analysis using Kaplan-meier method showed that the site of the tumor, gender, performance status, stage at presentation and tumor histopathology all had significant prognostic effect on EFS and OS (p<0.0001). Conclusion: Factors affecting the prognosis of patients with neuroendocrine tumors include; tumor{u2019}s histology, site, stage, patient{u2019}s gender and performance status. On multivariate analysis, the independent predictors of OS were histology of the tumor (P=0.001), patients{u2019} PS (P=0.039) and tumor stage (P<0.001). Larger scale prospective studies are needed for better understanding of this rare type of tumors